Relationship between elevated monocyte-HDL ratio, an inflammatory marker, with smoking
Objective: It has been shown that the monocyte/HDL ratio may be a new marker of inflammation and oxidative stress. In this study, it was aimed to investigate the monocyte / HDL ratio levels and related factors of smokers and non-smokers.
Method: 84 people between the ages of 18-65 who applied to the Family Medicine Clinic of Kütahya SBÜ Evliya Çelebi Training and Research Hospital for 3 months as of December 2019 were included in the study. A questionnaire form consisting of the a personal and clinical information form consisting of 13 questions and Fagerström Nicotine Dependence Test were used as data collection tools. In addition, HDL cholesterol and complete blood count in hemogram were performed from blood samples taken from the patients. Chi-square, Mann Whitney U and Spearman correlation tests were used to analyze the data. Statistical significance value was accepted as p <0.05.
Results: In this study, there was no statistically significant difference between smoking and non-smoking groups in terms of age groups, gender, chronic disease and regular medication use (p>0.05). Of the smoking participants 13.1% (n=11) were in the high addiction group, and 4.8% (n=4) in the very high addiction group according to the FNBT scale. The mean erythrocyte (p <0.001), hemoglobin (p=0.015), hematocrit (p=0.005), monocyte (p <0.001), HDL (p=0.005), MNO (p <0.001) in smoking patients were significantly higher than non-smoking patients.
Conclusion: Monocyte / HDL ratio can be used as a simple, easy and cost-effective marker that can be used to predict inflammation and endothelial dysfunction in smokers.
References
- World Health Organization. WHO report on the global tobacco epidemic, 2017. Monitoring tobacco use and prevention policies. https://www.who.int/tobacco/global_report/2017/en/ adresinden 05.07.2020 tarihinde erişilmiştir.
- Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372–7.
- Hessler JR, Robertson AL, Jr. Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-29.
- Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764–72.
- Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL- 6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 2006; 80:1156–64.
- Canpolat U, Cetin EH, Cetin S, Aydin S, Akboga MK, Yayla C, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost 2016;22: 476–82.
- Koçak HE, Acipayam H, Elbistanlı MS, Yiğider AP, Alakhras W, Kıral MN, et al. Is the monocyte/HDL ratio a prognostic marker of idiopathic sudden hearing loss? Otolaryngol Pol 2016; 31:26–30.
- Libby P. Inflammation in atherosclerosis. Arteriosclerosis, thrombosis, vascular biology 2012; 32(9): 2045-51.
- Kanbay M, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014; 46(8):1619-25.
- Yılmaz M. and Kayançiçek H. A new inflammatory marker: elevated monocyte to HDL cholesterol ratio associated with smoking. J Clin Med 2018:7(4):76.
- Fagerstrom KO, Schneider NG. Measuring nicotine dependence a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989; 12: 159- 82.
- Heatherton F, Kozlowski L.T, Frecker RC, Fagerstrom KO. The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addictions 1991; 86:1119-27.
- Uysal MA, Kadakal F, Karşıdağ Ç, Bayram NG, Uysal Ö, Yılmaz V. Fagerstrom test for nicotine dependence: reliability in a Turkish sample and factor analysis. Tuberk Toraks 2004; 52: 115-21.
- Chalouhi N, Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. Cigarette smoke and inflammation: Role in cerebral aneurysm formation and rupture. Mediat In- flamm 2012; 2012: 271582.
- Mannam P, Rauniyar N, Lam TT, Luo R, Lee PJ, Srivastava A. MKK3 influences mitophagy and is involved in cigarette smoke-induced inflammation. Free Radic Biol Med 2016;101:102–15.
- Wu YP, Cao C, Wu YF, Li M, Lai TW, Zhu C, Li W. Activating transcription factor 3 represses cigarette smoke-induced IL6 and IL8 expression via suppressing NF-κB activation. Toxicol Lett 2017; 270: 17–24.
- Mc Evoy JW, Nasir K, De Filippis AP, Lima JA, Bluemke, DA, Hundley WG, Polak JF. Relationship of cigarette smoking with inflammation and subclinical vascular disease: The Multi- Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35: 1002–10.
- Li H, Srinivasan SR, Chen W, Xu JH, Li S, Berenson GS. Vascular abnormalities in asymptomatic, healthy young adult smokers without other major cardiovascular risk factors: The Bogalusa Heart Study. Am J Hypertens 2005; 18: 319–24.
- Luo HL, Zang WJ, Lu J, Yu XJ, Lin YX, Cao YX. The protective effect of captopril on nicotine-induced endothelial dysfunction in rat. Basic Clin Pharmacol Toxicol 2006; 99: 237–45.
- Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Mono- cytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013;62(17):1541–51.
- Hessler JR, Robertson AL, Chisolm GM. LDL-induced cyto- toxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32(3):213–29.
- Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000;73(3):231–6.
- Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044(2):275–83.
- Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009;16(6):667–75.
- Murphy AJ, Woollard KJ. High-density lipoprotein: a po- tent inhibitor of inflammation. Clin Exp Pharmacol Physiol 2010;37(7):710–8.
- Yvan-Charvet L, Pagler T, Gautier EL. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell pro- liferation. Science 2010;328(5986):1689–93.
- Kormaz A, Demir M, Unal S, et al. Monocyte-to-high density lipoprotein ratio (MHR) can predict the significance of angio- graphically intermediate coronary lesions. Int J Cardiovas Acad 2017;3:16–20. doi:10.1016/j.ijcac.2017.05.008.
- Bolayir A, Gokce SF, Çiğdem B, et al. Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol Neurochir Pol 2018;52(2):150–5. doi:10.1016/j. pjnns.2017.08.011.
- Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Covic A. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014; 46: 1619–25.
- Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya E.B, Çay S, Oto A. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015; 17: 1807–15.
- 31. Cetin, EH, Cetin MS, Canpolat U, Aydin S, Topaloglu S, Aras D. et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med 2015; 9: 967–77.
- Karatas MB, Canga Y, Ozcan KS, Ipek G, Gungor B, Onuk T, et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary interven- tion. A. J Emerg Me. 2016; 34: 240–4.
- Acikgoz N, Kurtoglu E, Yagmur J, Kapicioglu Y, Cansel M, Ermis N. Elevated monocyte to high-density lipoprotein cholesterol ratio and endothelial dysfunction in Behçet disease. Angiology 2018; 69: 65–70.
